3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Propofol
9
Sevoflurane
7
Rituximab
7
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Trastuzumab
5
Enoxaparin
5
Bevacizumab
5
Nivolumab
4
Carboplatin
4
Capecitabine
4
Bupivacaine
4
trametinib
3
pirtobrutinib
3
pembrolizumab
3
dabrafenib
3
atezolizumab
3
apixaban
3
Lenalidomide
3
Indocyanine Green
3
Gemcitabine
3
Docetaxel
3
Cyclophosphamide
3
zanubrutinib
2
venetoclax
2
trastuzumab deruxtecan
2
ribociclib
2
polyethylene glycol 3350
2
pertuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Recruiting
×
gadodiamide
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled